G-CAN 2019 Fifth Annual Meeting
AGENDA
November 8, 2019
Crowne Plaza Midtown Hotel
590 West Peachtree Street Northwest
Atlanta, GA 30308

CONFERENCE REGISTRATION: www.123signup.com/g-canmeeting

Breakfast and sign-in at 7:30 am; meeting 8:00 am to 4:30 pm

8:00 – 8:15 Welcome and Introduction to G-CAN, Recognition of Industry Sponsors
   Founding G-CAN Co-Directors: Robert Terkeltaub (President) and Hyon Choi (VP and Treasurer)

8:15 – 10:00 Core Issues in Gout and Hyperuricemia
   Moderators: Fred Lioté and Robert Terkeltaub
   8:30 – 8:45 Impact of CVD Diet on Comorbidity of Gout and Serum Urate Levels. Stephen Juraschek, Baltimore
   8:45 – 9:00 Mendelian Randomization Update: Serum Urate and Chronic Kidney Disease. Hyon Choi, Boston
   9:00 – 9:15 Mendelian Randomization Update 2. Gout and Comorbidities. Tanya Major, New Zealand
   9:15 – 9:30 Planning a Clinical Trial to Resolve the Gout Guideline Conflicts and Comorbidity Endpoints. Dan Solomon, Boston
   9:45 – 10:00 OA and Gout. Michael Pillinger, New York

10:00 – 10:15 Break

10:15 – 11:35 Basic-Translational Gout Research
   Moderators: Tony Merriman and David Mount
   10:15 – 10:35 New Developments in Xanthine Oxidoreductase Biology. Alex So, Lausanne
   10:35 – 10:55 Monocyte Inflammatory Training and Histone Modification in Gout. Leo Joosten, Neijmingen
   10:55 – 11:15 Novel Markers of the Inflammatory State in Gout. Robert Terkeltaub, La Jolla

11:35 – 12:15 G-CAN Young Investigator Poster Session
   From 11:35 to 12:15 a guided poster tour led by Michael Pillinger is offered as an option; starts at Poster #1 and ends at Poster #20.
   1. Jie Lu, Qingdao, China; Changgui Li, Mentor. Hyperuricemia predisposes to the onset of diabetes via promoting pancreatic β-Cell death in uricase deficiency mice.
   2. Natalie McCormick, Boston, US; Hyon Choi, Mentor. From a potential solution to part of the problem: Analysis of public-payer spending and price trends for brand-name and generic colchicine and other gout medications.
   5. Nick Sumpter, Dunedin, New Zealand; Tony Merriman, Mentor. Association of a gout polygenic risk score with disease severity phenotypes amongst Caucasian gout patients in three independent cohorts.
7. **Medeea Badii**, Cluj-Napoca, Romania; **Leo Joosten, Mentor.**  
Downregulation of type 1 interferon signaling pathway by uric acid exposure in primary human mononuclear cells.

8. **Sarah Stewart**, Auckland, New Zealand; **Nicola Dalbeth, Mentor.**  
a. Article placement order in rheumatology journals: A content analysis focusing on crystal arthritis articles.  
b. How are flares reported in long-term gout clinical trials? A content analysis of randomized controlled trials.

9. **Philip Robinson**, Brisbane, Australia; **Nicola Dalbeth, Mentor.**  
a. Colchicine prophylaxis of gout flares when commencing allopurinol is very cost effective: A health economic analysis.  
b. Adverse events during colchicine use: A systematic review and meta-analysis of randomised controlled trial events.

10. **Vicky Tai**, Auckland, New Zealand; **Nicola Dalbeth, Mentor.**  
Do serum urate-associated genetic variants differentially contribute to gout risk according to body mass index? Analysis of the UK Biobank.

11. **Orsolya Gaal**, Cluj-Napoca, Romania; **Leo Joosten, Mentor.**  
The role of IGF1R in urate-induced inflammation.

12. **Andrew Shaffer**, Birmingham, US; **Angelo Gaffo, Mentor.**  
Longitudinal variation in repeat serum urate levels: Relationship with hyperuricemia classification.

13. **Loredana Peca**, Cluj-Napoca, Romania; **Leo Joosten, Mentor.**  
Interleukin-1 receptor antagonist 86-bp VNTR gene polymorphism and circulating IL-1Ra concentrations in Romanian patients with gout.

14. **Fatima Tahzeeb**, Gothenburg, Sweden; **Mats Dehlin, Mentor.**  
The association between urate and CSF markers of Alzheimer's disease in a population-based sample of 70-Year-Olds.

15. **Mike Frecklington**, Auckland, New Zealand; **Nicola Dalbeth, Mentor.**  
The effects of worn and new footwear on plantar pressure in people with gout.

16. **Youssef Roman**, Hilo, US; **Deborah A. Taira, Mentor.**  
Prevalence of rs2231142 in ABCG2 parallels the reported higher prevalence of hyperuricemia and gout in Filipinos than non-Filipinos.

17. **Ioana Hotea**, Cluj-Napoca, Romania; **Leo Joosten, Mentor.**  
Alpha-1-antitrypsin and IL-1 receptor antagonist in relation to serum urate and inflammatory markers in patients: Comparison between patients with gout, asymptomatic hyperuricaemia and healthy controls.

18. **Ritch te Kampe**, Maastricht, The Netherlands; **Tim Jansen, Mentor.**  
Sex differences in the clinical profile among gout patients: Cross-sectional analyses of an observational study.

19. **Ying Chen**, Qingdao, China; **Changgui Li, Mentor.**  
Prevalence and trends of hyperuricemia among residents aged 18 to 40 years old in coastal areas of Shandong Province, China 2004-2014.

20. **Lindsay Helget**, Omaha, US; **Ted R. Mikuls, Mentor.**  
The prevalence, incidence, and burden of gout in the Veterans Health Administration from 2005-2014.

**12:15 – 12:30 Lunchboxes Become Available to be Picked Up**  
Participants will pick up their lunches and return for the Young Investigator Oral Presentations.

**12:30 – 13:30 G-CAN Young Investigator Symposium Working Lunch Session**  
Five Oral Presentations moderated by Alex So and Tuhina Neogi, 12 minutes each

1. **Gabriela Sandoval-Plata**, Nottingham, UK; **Abhishek Abhishek, Mentor**  
Asymptomatic monosodium urate crystal deposition associates with increased expression of pro-inflammatory genes.

2. **Patricia Grieslaw de Oliveira**, LaJolla, US; **Ru Liu Bryan, Mentor**  
A novel ecto-enzymatic macrophage metabolic regulation system in monosodium urate crystal-induced inflammation.

3. **Gabriela Angélica Martinez-Nava**, Mexico City, Mexico; **Carlos Pineda, Mentor**  
Gut dysbiosis in patients with gout and individuals with asymptomatic hyperuricemia.

4. **Chio Yokose**, Boston, US; **Hyon Choi, Mentor**  
The effects of a low-fat, Mediterranean or low-carbohydrate diet on serum urate.

5. **2019 Ralph H. Schumacher Memorial Young Investigator Lecture**  
Introduction by Dr. Tuhina Neogi  
**Kensuke Nishimiya**, Miyagi, Japan; **Guillermo Tearney, Mentor**  
A novel approach for uric acid crystal detection in human coronary plaques ex-vivo with cross-polarized micro-OCT.
13:30 – 14:00  Core Issues in Gout and Hyperuricemia: Asia-based Perspective  
Moderators: Abhishek Abhishek and Hyon Choi

13:30 – 13:50  2019 G-CAN Clinical Research Distinguished Lecture: Gout in China and a Center-based Treatment Model. Changgui Li, Qingdao, China

13:50 – 14:00  Contemporary Epidemiology of Gout in Korea. Jung-Soo Song, Korea

14:00 – 14:30  New Developments in CPPD  
Moderators: Fred Lioté and Tuhina Neogi

14:00 – 14:15  CPPD Arthritis Flare Update. Tristan Pascart, France.
14:15 – 14:30  CPPD: The ACR/EULAR Classification Project. Abhishek Abhishek/Hyon Choi

14:30 – 15:00  Update on selected G-CAN Projects  
Moderators: Robert Terkeltaub and Alex So

14:30 – 14:45  Update on G-CAN Nomenclature and Language Projects: David Bursill
14:45 – 15:00  Management of Gout in CKD: Lisa Stamp and Angelo Gaffo, with Jessica Pisaniello and Hamish Farquhar

15:00 – 15:10  Break

15:10 – 16:10  Core Issues in Gout and Hyperuricemia and Crystal Arthropathy  
Moderators: Hyon Choi and David Mount

15:10 – 15:25  Perspective on Advances in Genetics of Gout. Tony Merriman, New Zealand
15:25 – 15:40  Further Perspective on Advances in Genetics of Gout. Hiro Matsuo, Japan
15:40 – 15:55  Comorbidity Clusters in Gout: Implications for Gout Prognosis and Future Comorbidity. Ed Roddy, UK
15:55 – 16:10  Predicting Development of Gout in Individuals with Hyperuricaemia: The TIGER Study. Nicola Dalbeth, Auckland

16:10 – 16:25  Discussion Time

16:25 – 16:30  Concluding Comments and Discussion  
Robert Terkeltaub and Hyon Choi

16:30  Meeting Adjourns

---

Thank you to G-CAN’s industry supporters

Roundtable Sponsor and Sponsor of Young Investigator Session

HORIZON PHARMA

Sponsors

AstraZeneca, Selecta Biosciences, SOBI, Takeda

Affiliate Sponsors

TEIJIN

Gout, Hyperuricemia and Crystal-Associated Disease Network, www.g-can.org
Oral Presentation Abstracts

1. **Gabriela Sandoval-Plata**
Sandoval-Plata, G., Morgan, K., Guetta-Baranes, T., Valdes, A., Doherty, M., Abhishek, A. **Asymptomatic monosodium urate crystal deposition associates with increased expression of pro-inflammatory genes.** University of Nottingham.

2. **Patricia Gnielislaw de Oliveira**
de Oliveira, P., Alabarse, P., Marinho, Y., Nuygen, N., Terkeltaub, R., Bryan, R. L. **A novel ecto-enzymatic macrophage metabolic regulation system in monosodium urate crystal-induced inflammation.** UCSD School of Medicine.

3. **Gabriela Angélica Martinez-Nava**

4. **Chio Yokose**
Yokose, C., Rai, S., McCormick, N., Lu, N., Curhan, G., Hyon, H.K. **The effects of a low-fat, Mediterranean or low-carbohydrate diet on serum urate.** Massachusetts General Hospital/Harvard Medical School.

5. **Kensuke Nishimiya**

Poster Presentation Abstracts

1. **Jie Lu**
Lu, J., He, Y., Cui, L., Li, C. **Hyperuricemia predisposes to the onset of diabetes via promoting pancreatic β-Cell death in uricase deficiency mice.** The Affiliated Hospital of Qingdao University.

2. **Natalie McCormick**
McCormick, N., Wallace, Z.S., Yokose, C., Jorge, A., Sacks, C., Hsu, J., Choi, H.K. **From a potential solution to part of the problem: Analysis of public-payer spending and price trends for brand-name and generic colchicine and other gout medications.** Massachusetts General Hospital/Harvard Medical School.

3. **Ken Cai**

4. **Ravi Narang**

5. **Nick Sumpter**

6. Chio Yokose

7. Medeea Badii

8. Sarah Stewart

9. Philip Robinson
b. Stewart, S., Yang, K., Atkins, K., Dalbeth, N., Robinson, P. Adverse events during colchicine use: A systematic review and meta-analysis of randomised controlled trial events. Royal Brisbane & Women’s Hospital.

10. Vicky Tai

11. Orsolya Gaal

12. Andrew Shaffer

13. Loredana Peca

14. Fatima, Tahzeeb

15. Mike Frecklington
Frecklington, M., Dalbeth, N., McNair, P., Vandal, A.C., Gow, P. The effects of worn and new footwear on plantar pressure in people with gout. AUT University.
16. **Youssef Roman**  
Roman, Y., Tiirikainen, M., Riel, J. *Prevalence of rs2231142 in ABCG2 parallels the reported higher prevalence of hyperuricemia and gout in Filipinos than non-Filipinos.* University of Hawaii.

17. **Ioana Hotea**  

18. **Ritch te Kampe**  

19. **Ying Chen**  

20. **Lindsay Helget**  